Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer
ShareXFacebook

(MedPage Today) -- The FDA approved durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval was based on results from the phase...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Brain Changes Linked With Speech-in-Noise Impairment
MedPage Today

Brain Changes Linked With Speech-in-Noise Impairment

(MedPage Today) -- Difficulty understanding speech in background noise was tied to brain changes in speech-processing networks and may be an early behavioral marker of neural vulnerability before cognitive decline, a study of older adults suggested...

Read more →
Advertisement